| Dr Lesley H Lee, MD | |
|
128 N George St, York, PA 17401-1117 | |
| (717) 848-6116 | |
| (717) 848-6215 |
| Full Name | Dr Lesley H Lee |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 128 N George St, York, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063581742 | NPI | - | NPPES |
| 010039550 | Medicaid | VA | |
| 1024620520002 | Medicaid | PA | |
| 189534 | Other | VA | ANTHEM |
| 299066 | Other | VA | AMERIGROUP |
| 546001103002 | Other | VA | TRICARE |
| 0072 | Other | VA | CAREFIRST BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 0101055993 (Virginia) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD056801L (Pennsylvania) | Primary |
| Entity Name | Uhs Of Fairmount Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215902168 PECOS PAC ID: 2466359435 Enrollment ID: O20031217000664 |
News Archive
A new therapy under development for the treatment of irritable bowel syndrome with diarrhea predominance appears to provide significant improvements in measures of quality of life, according to a study presented at the 69th Annual Meeting of the American College of Gastroenterology.
Bilirubin, a yellow-orange pigment, is formed after the breakdown of red blood cells and is eliminated by the liver. It's not only a sign of a bruise, it may provide cardiovascular benefits, according to a large-scale epidemiology study.
Atrial fibrillation is one of the most common complications following heart surgery, affecting one in three patients. This adverse side-effect, with symptoms such as palpitations, dizziness, shortness of breath or tightness in the chest, can normally be suppressed with sometimes strong medication.
YM BioSciences Inc., today reported that the Phase I/II clinical trial for its orally available JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis has been expanded to five sites. Of the additional sites, the Stanford Cancer Center (Stanford, California) under Principal Investigator Jason Gotlib, MD has already commenced enrolling patients.
Academics and healthcare professionals from across Greater Manchester as well as people with a diagnosis of dementia and family carers have teamed up to devise a new training programme for general hospital staff.
› Verified 4 days ago
| Entity Name | Uhs Of Pennsylvania, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124091715 PECOS PAC ID: 3971407438 Enrollment ID: O20050913000388 |
News Archive
A new therapy under development for the treatment of irritable bowel syndrome with diarrhea predominance appears to provide significant improvements in measures of quality of life, according to a study presented at the 69th Annual Meeting of the American College of Gastroenterology.
Bilirubin, a yellow-orange pigment, is formed after the breakdown of red blood cells and is eliminated by the liver. It's not only a sign of a bruise, it may provide cardiovascular benefits, according to a large-scale epidemiology study.
Atrial fibrillation is one of the most common complications following heart surgery, affecting one in three patients. This adverse side-effect, with symptoms such as palpitations, dizziness, shortness of breath or tightness in the chest, can normally be suppressed with sometimes strong medication.
YM BioSciences Inc., today reported that the Phase I/II clinical trial for its orally available JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis has been expanded to five sites. Of the additional sites, the Stanford Cancer Center (Stanford, California) under Principal Investigator Jason Gotlib, MD has already commenced enrolling patients.
Academics and healthcare professionals from across Greater Manchester as well as people with a diagnosis of dementia and family carers have teamed up to devise a new training programme for general hospital staff.
› Verified 4 days ago
| Entity Name | Thrive Counseling Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215181300 PECOS PAC ID: 0749458420 Enrollment ID: O20120416000069 |
News Archive
A new therapy under development for the treatment of irritable bowel syndrome with diarrhea predominance appears to provide significant improvements in measures of quality of life, according to a study presented at the 69th Annual Meeting of the American College of Gastroenterology.
Bilirubin, a yellow-orange pigment, is formed after the breakdown of red blood cells and is eliminated by the liver. It's not only a sign of a bruise, it may provide cardiovascular benefits, according to a large-scale epidemiology study.
Atrial fibrillation is one of the most common complications following heart surgery, affecting one in three patients. This adverse side-effect, with symptoms such as palpitations, dizziness, shortness of breath or tightness in the chest, can normally be suppressed with sometimes strong medication.
YM BioSciences Inc., today reported that the Phase I/II clinical trial for its orally available JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis has been expanded to five sites. Of the additional sites, the Stanford Cancer Center (Stanford, California) under Principal Investigator Jason Gotlib, MD has already commenced enrolling patients.
Academics and healthcare professionals from across Greater Manchester as well as people with a diagnosis of dementia and family carers have teamed up to devise a new training programme for general hospital staff.
› Verified 4 days ago
| Entity Name | Supportive Care Of Pennsylvania Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174992275 PECOS PAC ID: 0143521211 Enrollment ID: O20151214002225 |
News Archive
A new therapy under development for the treatment of irritable bowel syndrome with diarrhea predominance appears to provide significant improvements in measures of quality of life, according to a study presented at the 69th Annual Meeting of the American College of Gastroenterology.
Bilirubin, a yellow-orange pigment, is formed after the breakdown of red blood cells and is eliminated by the liver. It's not only a sign of a bruise, it may provide cardiovascular benefits, according to a large-scale epidemiology study.
Atrial fibrillation is one of the most common complications following heart surgery, affecting one in three patients. This adverse side-effect, with symptoms such as palpitations, dizziness, shortness of breath or tightness in the chest, can normally be suppressed with sometimes strong medication.
YM BioSciences Inc., today reported that the Phase I/II clinical trial for its orally available JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis has been expanded to five sites. Of the additional sites, the Stanford Cancer Center (Stanford, California) under Principal Investigator Jason Gotlib, MD has already commenced enrolling patients.
Academics and healthcare professionals from across Greater Manchester as well as people with a diagnosis of dementia and family carers have teamed up to devise a new training programme for general hospital staff.
› Verified 4 days ago
| Entity Name | Eastern Pennsylvania Physician Alliance, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902440621 PECOS PAC ID: 8325478662 Enrollment ID: O20200428001935 |
News Archive
A new therapy under development for the treatment of irritable bowel syndrome with diarrhea predominance appears to provide significant improvements in measures of quality of life, according to a study presented at the 69th Annual Meeting of the American College of Gastroenterology.
Bilirubin, a yellow-orange pigment, is formed after the breakdown of red blood cells and is eliminated by the liver. It's not only a sign of a bruise, it may provide cardiovascular benefits, according to a large-scale epidemiology study.
Atrial fibrillation is one of the most common complications following heart surgery, affecting one in three patients. This adverse side-effect, with symptoms such as palpitations, dizziness, shortness of breath or tightness in the chest, can normally be suppressed with sometimes strong medication.
YM BioSciences Inc., today reported that the Phase I/II clinical trial for its orally available JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis has been expanded to five sites. Of the additional sites, the Stanford Cancer Center (Stanford, California) under Principal Investigator Jason Gotlib, MD has already commenced enrolling patients.
Academics and healthcare professionals from across Greater Manchester as well as people with a diagnosis of dementia and family carers have teamed up to devise a new training programme for general hospital staff.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lesley H Lee, MD 200 N 7th Street, Lebanon, PA 17046-5040 Ph: (717) 273-1710 | Dr Lesley H Lee, MD 128 N George St, York, PA 17401-1117 Ph: (717) 848-6116 |
News Archive
A new therapy under development for the treatment of irritable bowel syndrome with diarrhea predominance appears to provide significant improvements in measures of quality of life, according to a study presented at the 69th Annual Meeting of the American College of Gastroenterology.
Bilirubin, a yellow-orange pigment, is formed after the breakdown of red blood cells and is eliminated by the liver. It's not only a sign of a bruise, it may provide cardiovascular benefits, according to a large-scale epidemiology study.
Atrial fibrillation is one of the most common complications following heart surgery, affecting one in three patients. This adverse side-effect, with symptoms such as palpitations, dizziness, shortness of breath or tightness in the chest, can normally be suppressed with sometimes strong medication.
YM BioSciences Inc., today reported that the Phase I/II clinical trial for its orally available JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis has been expanded to five sites. Of the additional sites, the Stanford Cancer Center (Stanford, California) under Principal Investigator Jason Gotlib, MD has already commenced enrolling patients.
Academics and healthcare professionals from across Greater Manchester as well as people with a diagnosis of dementia and family carers have teamed up to devise a new training programme for general hospital staff.
› Verified 4 days ago
Carolina Leonid Harbert, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1695 Roosevelt Ave Ste B, York, PA 17408 Phone: 717-851-5503 Fax: 717-798-3510 | |
Ademola Bello, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1001 S George St, York, PA 17403 Phone: 717-851-2304 Fax: 717-851-3374 | |
Shirin Sultana, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 3550 Concord Rd, York, PA 17402 Phone: 717-851-6340 Fax: 717-851-6349 | |
Lindsay Elizabeth Campbell, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3550 Concord Rd, York, PA 17402 Phone: 717-851-6340 Fax: 717-851-6349 | |
Dr. Nikita Eike, M.D Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 707 Loucks Rd, York, PA 17404 Phone: 717-718-1215 Fax: 717-854-5007 | |
Jimmy O Ibikunle, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2078 Bernays Dr, York, PA 17404 Phone: 717-764-2358 |